Quantum BioPharma Cuts Costs and Advances Lucid-MS into Phase 2 Trial for Progressive MS

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has reported a significant reduction in operating expenses for the second quarter of 2026, alongside a major regulatory milestone for its lead drug candidate. The company announced a 53% year-over-year decrease in operating expenses, bringing them to $2.29 million, and a 47% reduction in general and administrative expenses to $1.76 million. This financial discipline has strengthened its cash position, with combined cash, cash equivalents, and digital assets totaling approximately $9.5 million as of June 30, up from $4.1 million at the end of 2025. Management states that current liquidity is sufficient to fund planned operations to at least October 2027, assuming the first-half 2026 cash burn rate.

The most notable development came after the quarter-end when the U.S. Food and Drug Administration (FDA) approved Quantum's Investigational New Drug (IND) application for Lucid-MS. This clearance allows the company to proceed with a randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with progressive multiple sclerosis (MS). This is a pivotal step for Lucid-MS, a patented new chemical entity that has shown in preclinical models the ability to prevent and reverse myelin degradation, which is the underlying mechanism of MS.

This progress is particularly significant given the high unmet need in progressive MS, a form of the disease for which there are limited treatment options. The move into Phase 2 trials not only validates the scientific promise of Lucid-MS but also positions Quantum BioPharma as a potential key player in the neurodegenerative disease space. The company's focus on reducing costs while advancing its pipeline demonstrates a strategic approach to biopharmaceutical development, aiming to maximize value for shareholders.

In addition to its MS program, Quantum BioPharma is dedicated to building a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is advancing Lucid-MS, while also retaining a 19.84% ownership stake in Unbuzzd Wellness Inc., which markets the over-the-counter version of UNBUZZD. The agreement with Unbuzzd includes royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products for pharmaceutical and medical uses.

The reduction in expenses and the advancement of Lucid-MS into Phase 2 trials are critical for Quantum BioPharma's future. The company's ability to extend its cash runway through cost management provides a solid foundation for the upcoming clinical trial, which will be a major catalyst for the company. Investors and the medical community will be watching closely as Quantum BioPharma moves forward with its clinical development plans.

For more information on Quantum BioPharma and its latest updates, visit the company's newsroom at https://nnw.fm/QNTM.